Notably, TCR-T cell therapy offers distinct advantages over other cellular therapies, such as dendritic cell (DC) vaccines, CAR-T, and tumor-infiltrating lymphocyte (TIL) therapies, due to its unique capacity to target intracellular antigens presented by major histocompatibility complex (MHC) molecules. Here, HLA-C is linked to neoplasm.